News
PHVS
22.60
-3.95%
-0.93
Weekly Report: what happened at PHVS last week (0429-0503)?
Weekly Report · 3h ago
Weekly Report: what happened at PHVS last week (0422-0426)?
Weekly Report · 04/29 09:24
Bullish Two Hundred Day Moving Average Cross - PHVS
NASDAQ · 04/23 17:28
Weekly Report: what happened at PHVS last week (0415-0419)?
Weekly Report · 04/22 09:22
Pharvaris Is Maintained at Overweight by Morgan Stanley
Dow Jones · 04/15 16:56
Pharvaris Price Target Cut to $34.00/Share From $35.00 by Morgan Stanley
Dow Jones · 04/15 16:56
Morgan Stanley Maintains Overweight on Pharvaris, Lowers Price Target to $34
Benzinga · 04/15 16:45
Weekly Report: what happened at PHVS last week (0408-0412)?
Weekly Report · 04/15 09:21
Pharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatment
TipRanks · 04/15 01:25
Pharvaris files for automatic mixed securities shelf
Seeking Alpha · 04/12 20:34
Pharvaris NV Files For Mixed Shelf Offering; Size Not Disclosed
Benzinga · 04/12 20:21
Pharvaris N.V.’s High-Stakes Gamble: Navigating Clinical Trials and Regulatory Hurdles for Market Success
TipRanks · 04/12 06:00
Buy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid Financials
TipRanks · 04/12 05:39
Pharvaris Price Target Raised to $50.00/Share From $49.00 by JMP Securities
Dow Jones · 04/11 16:23
Pharvaris Is Maintained at Market Outperform by JMP Securities
Dow Jones · 04/11 16:23
JMP Securities Maintains Market Outperform on Pharvaris, Raises Price Target to $50
Benzinga · 04/11 16:13
Pharvaris Price Target Maintained With a $35.00/Share by Wedbush
Dow Jones · 04/11 14:10
Wedbush Reiterates Outperform on Pharvaris, Maintains $35 Price Target
Benzinga · 04/11 13:59
Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)
TipRanks · 04/11 12:15
Pharvaris Excels in HAE Treatment Advances
TipRanks · 04/11 08:40
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).